ECSP003525A - IL-8 IV RECEIVER ANTAGONISTS - Google Patents

IL-8 IV RECEIVER ANTAGONISTS

Info

Publication number
ECSP003525A
ECSP003525A EC2000003525A ECSP003525A ECSP003525A EC SP003525 A ECSP003525 A EC SP003525A EC 2000003525 A EC2000003525 A EC 2000003525A EC SP003525 A ECSP003525 A EC SP003525A EC SP003525 A ECSP003525 A EC SP003525A
Authority
EC
Ecuador
Prior art keywords
receiver antagonists
antagonists
receiver
chemokine
interleukin
Prior art date
Application number
EC2000003525A
Other languages
Spanish (es)
Inventor
Katherine L Widdowson
Gregory M Benson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ECSP003525A publication Critical patent/ECSP003525A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a nuevas fenil-ureas útiles en el tratamiento de estados de enfermedades mediados por la quimiocina interleucina-8(IL-8)This invention relates to novel phenyl ureas useful in the treatment of disease conditions mediated by interleukin-8 chemokine (IL-8)

EC2000003525A 1999-06-16 2000-06-12 IL-8 IV RECEIVER ANTAGONISTS ECSP003525A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13967499P 1999-06-16 1999-06-16

Publications (1)

Publication Number Publication Date
ECSP003525A true ECSP003525A (en) 2002-01-25

Family

ID=22487784

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2000003525A ECSP003525A (en) 1999-06-16 2000-06-12 IL-8 IV RECEIVER ANTAGONISTS
EC2000003528A ECSP003528A (en) 1999-06-16 2000-08-14 ANTAGONISTS OF THE RECEIVER OF IL - 8 VI

Family Applications After (1)

Application Number Title Priority Date Filing Date
EC2000003528A ECSP003528A (en) 1999-06-16 2000-08-14 ANTAGONISTS OF THE RECEIVER OF IL - 8 VI

Country Status (22)

Country Link
EP (1) EP1191934A4 (en)
JP (1) JP2003501471A (en)
KR (1) KR20020009635A (en)
CN (1) CN1494424A (en)
AR (1) AR029368A1 (en)
AU (1) AU766086B2 (en)
BR (1) BR0010985A (en)
CA (1) CA2377397A1 (en)
CZ (1) CZ20014490A3 (en)
EC (2) ECSP003525A (en)
HK (1) HK1044716A1 (en)
HU (1) HUP0202019A3 (en)
IL (1) IL146214A0 (en)
MX (1) MXPA01013287A (en)
NO (1) NO20016065L (en)
NZ (1) NZ515232A (en)
PE (1) PE20010319A1 (en)
PL (1) PL352218A1 (en)
TR (1) TR200103690T2 (en)
UY (1) UY26209A1 (en)
WO (1) WO2000076516A1 (en)
ZA (1) ZA200110203B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE98223T1 (en) * 1988-03-30 1993-12-15 Warner Lambert Co N-(((2,6-DISUBSTITUTED)PHENYL>N'-ARYLALKYL> UREAS AS ANTIHYPERCHOLESTEROLMIC AND ANTIATHEROSCLEROTIC AGENTS.
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (en) * 1996-08-15 1999-12-29 Smithkline Beecham Corp NEW COMPOUNDS CONTAINING GUANIDINE USEFUL AS ANTAGONISTS OF IL-8 RECEPTORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS AND PROCEDURE FOR THE PREPARATION OF INTERMEDIARIES.

Also Published As

Publication number Publication date
WO2000076516A1 (en) 2000-12-21
AR029368A1 (en) 2003-06-25
UY26209A1 (en) 2000-12-29
CZ20014490A3 (en) 2002-07-17
AU5748200A (en) 2001-01-02
IL146214A0 (en) 2002-07-25
BR0010985A (en) 2002-03-26
JP2003501471A (en) 2003-01-14
CA2377397A1 (en) 2000-12-21
NO20016065D0 (en) 2001-12-12
ZA200110203B (en) 2002-09-11
KR20020009635A (en) 2002-02-01
EP1191934A4 (en) 2004-02-04
PL352218A1 (en) 2003-08-11
AU766086B2 (en) 2003-10-09
CN1494424A (en) 2004-05-05
TR200103690T2 (en) 2002-05-21
NO20016065L (en) 2001-12-12
PE20010319A1 (en) 2001-05-24
HUP0202019A2 (en) 2002-10-28
NZ515232A (en) 2004-02-27
MXPA01013287A (en) 2002-06-04
HK1044716A1 (en) 2002-11-01
ECSP003528A (en) 2002-01-25
HUP0202019A3 (en) 2003-03-28
EP1191934A1 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
ATE419845T1 (en) IL-8 RECEPTOR ANTAGONISTS
NO986110L (en) IL-8 receptor antagonists
JO2796B1 (en) Il-8 receptor antagonists
TR199900318T2 (en) IL-8 receptor antagonists.
UY26601A1 (en) IL-8 RECEPTOR ANTAGONISTS
EP1576011A4 (en) INHIBITION OF IL-17 PRODUCTION
BR0313109A (en) Cyclobutene-1,2-diones 3,4-disubstituted as cxc chemokine receptor ligands
EA200970051A1 (en) ANTAGONIST RECEPTOR IL-8
CR8659A (en) PGD2 RECEIVER ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
PT1129096E (en) CRF RECEPTOR ANTAGONISTS AND METHODS OF TREATMENT RELATED TO THEM
WO2005000231A3 (en) Il-8 receptor antagonists
NZ514696A (en) IL-8 receptor antagonists
BR0109002A (en) IL-8 antagonist receptors
MY128154A (en) Il-8 receptor antagonists
ECSP003525A (en) IL-8 IV RECEIVER ANTAGONISTS
WO2001068569A3 (en) Il-8 receptor antagonists
HK1045257A1 (en) Il-8 receptor antagonists
MY143477A (en) Il-8 receptor antagonists
UY26206A1 (en) IL-8 RECEPTOR ANTAGONISTS.
WO2000072800A3 (en) Il-8 receptor antagonists
HK1045256A1 (en) Il-8 receptor antagonists
ECSP003527A (en) IL RECEIVER ANTAGONISTS - 8 V
AP2002002606A0 (en) IL-8 receptor antagonists.
WO2001064165A3 (en) Il-8 receptor antagonists
ECSP003529A (en) ANTAGONISTS OF THE RECEIVER OF IL - 8 VII